Partex.AI Announces Strategic Collaboration with Changchun GeneScience Pharmaceutical to Accelerate AI-Driven Drug Innovation

Partex.AI, a pioneering AI-driven biopharmaceutical company, today announced a strategic collaboration with Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), a leading biopharmaceutical company in China, to accelerate the discovery, development, and commercialization of innovative therapies.

This collaboration brings together GenSci’s decades of expertise in developing innovative medicines across major disease areas with Partex.AI’s advanced Foundation Model and AI-powered drug discovery and development platform. Together, the companies aim to enhance target discovery, screen and optimize novel drug candidates, and expand GenSci’s core therapeutic areas with a view toward global commercialization.

Under the partnership, Partex.AI’s proprietary AI technologies will be deployed across key stages of the drug development lifecycle to support faster, more informed decision-making and improve R&D efficiency. The collaboration is expected to advance promising programs and help address unmet medical needs across multiple indications.

Xian Xuan, PhD, Head of the Artificial Intelligence Drug Institute at GenSci, commented, “We are pleased to collaborate with Partex.AI and fully leverage its cutting-edge technologies to advance target discovery and enhance indications. This partnership will strengthen our capabilities in AI-enabled drug development and help bring innovative treatment options from China to patients worldwide.”

Zhao Lisha, Head of Partex.AI Asia, added, “This strategic collaboration reflects the complementary strengths of Partex.AI and GenSci. By combining GenSci’s deep therapeutic expertise with our AI-driven platform, we aim to accelerate high-potential programs and support data-driven decisions across the full drug development process.”

Artificial Intelligence is a core pillar of GenSci’s innovation strategy, supporting drug discovery, development, patient services, and commercialization. GenSci’s in-house AI platforms, including GenMOL and GenROS, have already delivered measurable improvements in R&D efficiency. The collaboration with Partex.AI further strengthens GenSci’s AI-driven approach and long-term commitment to innovation.

About Partex.AI

Partex.AI is a pioneering AI-driven biopharmaceutical company dedicated to transforming drug discovery and development. Leveraging cutting-edge artificial intelligence technologies, Partex.AI accelerates the identification, development, and commercialization of breakthrough therapies. Its proprietary platform enables advanced target discovery, drug candidate optimization, therapeutic prediction, and faster in- and out-licensing, helping bring innovative medicines to patients sooner.

About Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”)

Changchun GeneScience Pharmaceutical Co., Ltd. is a leading biopharmaceutical company in China, specializing in pediatric and women’s health, with additional focus across Endocrinology, Metabolic, Immunology/Respiratory, and Oncology. Founded in 1997, GenSci employs over 9,000 people and integrates research, development, manufacturing, and commercialization of innovative therapies. The company is a subsidiary of Changchun High-Tech Industries (Group) and is headquartered in Changchun, China.